Prostate Cancer | Clinical

January 15, 2021

Naomi Haas, MD, discusses the current areas of ongoing research in the treatment landscape for patients with prostate cancer.

January 12, 2021

During a Targeted Oncology Case-Based Peer Perspectives event, Arash Rezazadeh Kalebasty, MD, discussed genomic testing and evidence-based treatment of a 60-year-old male patient with prostate cancer.

January 08, 2021

The FDA has updated the Prescribing Information for the approved agent darolutamide to include improvement in overall survival in patients with non-metastatic castration-resistant prostate cancer, as well as other secondary end point data, from the phase 3 ARAMIS clinical trial.

January 03, 2021

Prostate-specific membrane antigen–targeting diagnostic agents are moving forward toward greater clinical use in PET imaging for prostate cancer.

January 02, 2021

Maha Hussain, MD, discusses the current role of PARP inhibitors in the treatment landscape of prostate cancers and where she sees this therapeutic approach evolving in the coming years.

January 01, 2021

During a debate at the 27th Annual Prostate Cancer Foundation Virtual Scientific Retreat, Daniel Spratt, MD, debated Daniel Lin, MD, on the subject of genomic classifiers in prostate cancer.

December 28, 2020

Anthony A. Meluch, MD, medical oncologist, Tennessee Oncology, discussed treatment options for high-risk adenocarcinoma of the prostate based on the case of a 75-year-old patient during a Targeted Oncology Case-Based Peer Perspectives event.

December 26, 2020

During a Targeted Oncology Case Based Peer Perspective event, Mayer N. Fishman, MD, PhD, discussed the case of a 60-year-old man with progressing prostate cancer.

December 21, 2020

Experts in genitourinary cancer review 2 clinical cases and address major changes in the management of patients with castration-resistant prostate cancer.

December 18, 2020

The FDA has granted approval to oral relugolix as treatment of patients with advanced prostate cancer.